Korro Bio

KRRO

Market cap $292M

Overview Fund Activity

31.14 USD

-0.21

0.67%

At close Updated Sep 16, 4:00 PM EDT

1 day

-0.67%

5 days

-14.14%

1 month

57.91%

3 months

133.61%

6 months

24.26%

Year to date

-24.09%

1 year

-23.79%

5 years

-97.44%

10 years

-95.45%

About: Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Employees: 92

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

6.96% less ownership

Funds ownership: 103.35% [Q1] → 96.4% (-6.96%) [Q2]

8% less funds holding

Funds holding: 75 [Q1] → 69 (-6) [Q2]

32% less capital invested

Capital invested by funds: $169M [Q1] → $115M (-$54.2M) [Q2]

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

20% downside

Avg. target

$91

191% upside

High target

$147

372% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital Keay Nakae	$25	Buy Maintained	13 Aug 2025
Raymond James Steven Seedhouse	$147	Strong Buy Maintained	13 Aug 2025
HC Wainwright & Co. Mitchell S. Kapoor	$90	Buy Maintained	13 Aug 2025
HC Wainwright & Co. Mitchell Kapoor	$100	Buy Reiterated	24 Jul 2025

See Analyst Rankings

Financial journalist opinion

Korro to Participate in Upcoming Investor and Scientific Conferences

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September:

Korro to Participate in Upcoming Investor and Scientific Conferences

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) cohorts with no treatment emergent serious adverse events (SAEs) or dose limiting toxicities observed — European Medicines Agency (EMA) granted Orphan Drug Designation to KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) — Development candidate for Korro's rare metabolic disorder program will be announced by end of 2025 — Ended second quarter 2025 with $119.6 million in cash, cash equivalents and marketable securities CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2025 and provided a business update.

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro's investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare Conference Ram Aiyar, Ph.D.

Korro to Participate in Upcoming Investor Conferences

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2025 and provided a business update.

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported full-year 2024 financial results, and provided an update on recent progress and anticipated milestones.

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Korro to Present at the TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will also participate in 1x1 investor meetings at the conference.

Korro to Present at the TD Cowen 45th Annual Health Care Conference

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:

Korro to Participate in Upcoming Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™